Drug intelligence / Profile preview

Xianglianwan

Development stage: Unknown
Lead developer: Shanghai Hospital of Integrated Traditional Chinese and Western Medicine
Administration: Oral

Overview

Xianglianwan is a traditional Chinese medicine (TCM) formula traditionally used for gastrointestinal disorders such as dysentery and enteritis. It primarily consists of *Coptis chinensis* (Huanglian) and *Aucklandia lappa* (Mu Xiang). In modern clinical research, it is being investigated for its potential to enhance the efficacy of immunotherapy in patients with advanced malignant tumors. The drug is thought to work by modulating the intestinal microbiota and regulating inflammatory cytokines, thereby alleviating immune-related adverse events like enteritis and potentially exerting synergistic anti-tumor effects.

Brand names: Xianglianwan
Other names: Xianglian PillFangxianglian PillXiang Lian Wan

Beyond the preview

Go deeper on Xianglianwan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xianglianwan.

Explore the full profile